Skip to content

NANOVIRICIDES, INC.: 10-Q filed 2025-05-15

What NANOVIRICIDES, INC. reported in its quarterly report filed 2025-05-15 (fiscal Q3 2025): 34 published measures, 106 facts as tagged in accession 0001410578-25-001336.

This filing

Form
10-Q (quarterly report)
Filed
2025-05-15
Fiscal period
fiscal Q3 2025
Accession
0001410578-25-001336 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NANOVIRICIDES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-03-3110,031,960USD
At 2024-06-3012,822,853USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-03-318,833,049USD
At 2024-12-3110,386,579USD
At 2024-09-3010,107,791USD
At 2024-06-3011,464,077USD
At 2024-03-3110,651,570USD
At 2023-12-3112,451,136USD
At 2023-09-3012,968,510USD
At 2023-06-3014,865,630USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-03-312,542,590USD
At 2024-06-304,797,778USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-2,216,783USD90
2024-07-01 to 2025-03-31-7,371,085USD274
2024-10-01 to 2024-12-31-2,027,491USD92
2024-07-01 to 2024-09-30-3,126,811USD92
2024-01-01 to 2024-03-31-1,854,476USD91
2023-07-01 to 2024-03-31-5,938,159USD275
2023-10-01 to 2023-12-31-2,114,937USD92
2023-07-01 to 2023-09-30-1,968,746USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-07-01 to 2025-03-31-6,776,773USD274
2023-07-01 to 2024-03-31-4,834,171USD275

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2024-07-01 to 2025-03-3146,764USD274
2023-07-01 to 2024-03-3158,397USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-07-01 to 2025-03-314,568,349USD274
2023-07-01 to 2024-03-310USD275

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-07-01 to 2025-03-31-46,764USD274
2023-07-01 to 2024-03-31-58,397USD275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-03-31-146,745,980USD
At 2024-06-30-139,374,895USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-01-01 to 2025-03-3116,026,318shares90
2024-07-01 to 2025-03-3114,761,896shares274
2024-01-01 to 2024-03-3111,779,579shares91
2023-07-01 to 2024-03-3111,747,978shares275

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-01-01 to 2025-03-3116,026,318shares90
2024-07-01 to 2025-03-3114,761,896shares274
2024-01-01 to 2024-03-3111,779,579shares91
2023-07-01 to 2024-03-3111,747,978shares275

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-0.14USD/shares90
2024-07-01 to 2025-03-31-0.5USD/shares274
2024-01-01 to 2024-03-31-0.16USD/shares91
2023-07-01 to 2024-03-31-0.51USD/shares275

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-0.14USD/shares90
2024-07-01 to 2025-03-31-0.5USD/shares274
2024-01-01 to 2024-03-31-0.16USD/shares91
2023-07-01 to 2024-03-31-0.51USD/shares275

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-03-316,982,750USD
At 2024-06-307,512,463USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-2,249,156USD90
2024-07-01 to 2025-03-31-7,476,042USD274
2024-01-01 to 2024-03-31-1,908,403USD91
2023-07-01 to 2024-03-31-6,124,750USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-03-312,727,306USD
At 2024-06-304,970,520USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-03-311,198,911USD
At 2024-06-301,358,776USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2025-03-3113,545USD
At 2024-06-3019,747USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-01-01 to 2025-03-312,249,156USD90
2024-07-01 to 2025-03-317,476,042USD274
2024-01-01 to 2024-03-311,908,403USD91
2023-07-01 to 2024-03-316,124,750USD275

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-01-01 to 2025-03-311,282,251USD90
2024-07-01 to 2025-03-314,371,693USD274
2024-01-01 to 2024-03-311,214,661USD91
2023-07-01 to 2024-03-314,255,205USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-03-3116,071,950shares
At 2024-06-3013,144,055shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-03-312,542,590USD
At 2024-06-304,797,778USD
At 2024-03-313,257,240USD
At 2023-06-308,149,808USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-03-31155,578,860USD
At 2024-06-30150,838,832USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2025-03-3115,013,050USD
At 2024-06-3014,966,286USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-03-318,030,300USD
At 2024-06-307,453,823USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2025-03-31319,106USD
At 2024-06-30325,308USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-03-3132,616USD
At 2024-06-30262,467USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-07-01 to 2025-03-31-7,371,085USD274
2023-07-01 to 2024-03-31-5,938,159USD275

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-01-01 to 2025-03-31966,905USD90
2024-07-01 to 2025-03-313,104,349USD274
2024-01-01 to 2024-03-31693,742USD91
2023-07-01 to 2024-03-311,869,545USD275

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-01-01 to 2025-03-31189,114USD90
2024-07-01 to 2025-03-31576,477USD274
2024-01-01 to 2024-03-31187,889USD91
2023-07-01 to 2024-03-31562,209USD275

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2025-01-01 to 2025-03-312,068USD90
2024-07-01 to 2025-03-316,202USD274
2024-01-01 to 2024-03-312,067USD91
2023-07-01 to 2024-03-316,202USD275

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-07-01 to 2025-03-31149USD274
2023-07-01 to 2024-03-3149,808USD275

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-01-01 to 2025-03-3132,373USD90
2024-07-01 to 2025-03-31105,106USD274
2024-01-01 to 2024-03-3153,927USD91
2023-07-01 to 2024-03-31236,399USD275

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-01-01 to 2025-03-3132,373USD90
2024-07-01 to 2025-03-31104,957USD274
2024-01-01 to 2024-03-3153,927USD91
2023-07-01 to 2024-03-31186,591USD275

Inspect the source

Entity
NANOVIRICIDES, INC. / CIK 0001379006
Captured
2026-09-20T07:58:03.748Z
SEC response SHA-256
5d15adcbc42d7ac8bfebbf748da8ae31563dd5d02e790dc3e1b9bde076c805d2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001379006.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))